行情

COLL

COLL

Collegium Pharm
NASDAQ

实时行情|Nasdaq Last Sale

21.11
+0.10
+0.45%
交易中 13:24 01/28 EST
开盘
21.00
昨收
21.01
最高
21.50
最低
20.90
成交量
20.09万
成交额
--
52周最高
24.72
52周最低
10.01
市值
7.08亿
市盈率(TTM)
-62.2750
分时
5日
1月
3月
1年
5年

分析师评级

9位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

COLL 新闻

  • “病毒恐慌”现降温迹象 美元美股联袂上涨
  • FX168.45分钟前
  • 强生称正在研发新型冠状病毒防疫疫苗
  • 新浪财经.1小时前
  • 里士满联储1月制造业指数升至2018年以来的最高水平
  • 新浪财经.1小时前
  • 美国1月消费者信心指数涨幅超预期 升至5个月来高点
  • 新浪财经.1小时前

更多

所属板块

制药
+0.40%
制药与医学研究
+0.58%

热门股票

名称
价格
涨跌幅

COLL 简况

Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting. Xtampza ER is designed to provide adequate pain control while maintaining its extended-release drug release profile after being subjected to common methods of abuse and accidental misuse. ONSOLIS is a Transmucosal Immediate-Release Fentanyl (TIRF) film indicated for the management of breakthrough pain in cancer patients (BTPc), 18 years of age and older, who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.
展开

Webull提供Collegium Pharmaceutical Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。